Preface

The management of immunosuppressed patients, particularly those with haematological malignancies and allogeneic stem cell transplants, is complicated due to their increased risk of developing invasive fungal disease, which in turn increases morbidity, mortality and treatment costs. Delays in starting antifungal therapy are associated with increased mortality; however, the diagnosis of fungal infection remains complex and the unnecessary use of broad-spectrum antifungal agents is associated with increased treatment costs and the possible emergence of drug resistance. Thus, the management of patients at increased risk of invasive fungal disease remains the subject of active debate. This Supplement in the *Journal of Antimicrobial Chemotherapy* focuses on approaches to the management of such patients and we hope it will be of interest and clinical value to healthcare workers involved in their care.

Andrew J. Ullmann
Alan P. Johnson

Transparency declarations

A.J.U. has received research grants from MSD (Schering Plough) and is/was an advisor or received lecture honoraria from Astellas, Aicuris, Basilea, Gilead, MSD and Pfizer. A.P.J. has none to declare.